| Name | Title | Contact Details |
|---|
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"
Cylene Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infinity Care Solutions wants to take the time and trouble out of a normal pharmacy experience by not only providing you with traditional medications, but also offering you and your healthcare provider a choice. We know that no two patients are exactly the same and each requires specific knowledge and a team approach. It is our goal to meet this challenge head on. With our top-of-the-line, custom-made compounded products, and our impeccable customer service, our mission is for you to experience symptom relief like never before. Our pharmacy is built on a solid foundation of medical expertise and cutting edge pharmaceutical compounding methods that are unmatched, especially in the areas of topical hormone replacement therapy and topical pain medications.
Velocity Clinical Research, headquartered in Durham, NC, is a leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. The company has 18 sites across 12 US States. We place the care of the patient at the heart of everything we do. With over 35 years of experience running sites and more than 5500 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality.
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.